Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucose-dependent insulinotropic polypeptide (GIP) was recently linked to adipocyte metabolism and obesity-related metabolic disorders, including NAFLD, induced by an excess of saturated fatty acids (SFAs), but its role in vivo, as well as underlying mechanisms, is unknown.
|
19141695 |
2009 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Gastric inhibitory polypeptide (GIP) is postulated to be involved in type 2 diabetes mellitus and obesity.
|
19254363 |
2009 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucose-dependent insulinotropic polypeptide [also known as gastric inhibitory polypeptide (GIP)] and its receptor (GIPR) may link overnutrition to obesity, insulin resistance, and type 2 diabetes.
|
22237064 |
2012 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucose-dependent insulinotropic polypeptide is secreted after food consumption and gipr knockout mice fed a high-fat diet are protected against obesity and disturbances in glucose homeostasis.
|
22399504 |
2012 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
GIP is well known to contribute to HFD-induced obesity.
|
29406782 |
2018 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucose-dependent insulinotropic polypeptide (GIP) is closely related to diabetes and obesity, both of which are confirmed to increase the risk of coronary artery disease (CAD).
|
29765988 |
2018 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) has been identified in multiple genome-wide association studies (GWAS) as a contributor to obesity, and GIPR knockout mice are protected against diet-induced obesity (DIO).
|
30567927 |
2018 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
GIP also enhances long-chain triglyceride (LCT) diet-induced obesity and insulin resistance.
|
30990747 |
2019 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) is associated with obesity in human genome-wide association studies (GWAS).
|
31511854 |
2020 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
GIP analogues and the treatment of obesity-diabetes.
|
31756366 |
2020 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
GIP analogues augment bone strength by modulating bone composition in diet-induced obesity in mice.
|
31765668 |
2020 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
A dual incretin receptor agonist designed to co-activate GLP-1 and GIP receptors was recently shown to elicit robust improvements of glycemic control (mean haemoglobin A1c reduction of 1.94%) and massive body weight loss (mean weight loss of 11.3 kg) after 26 weeks of treatment with the highest dose (15 mg once weekly) in a clinical trial including overweight/obese patients with type 2 diabetes.
|
31443356 |
2019 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
A synthetic monomeric peptide triple receptor agonist, termed "Triagonist" that incorporates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon (Gcg) actions, was previously developed to improve upon metabolic and glucose regulatory benefits of single and dual receptor agonists in rodent models of diet-induced obesity and type 2 diabetes.
|
31730763 |
2020 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Ambiguity regarding the role of glucose-dependent insulinotropic polypeptide (GIP) in obesity arises from conflicting reports asserting that both GIP receptor (GIPR) agonism and antagonism are effective strategies for inhibiting weight gain.
|
31447324 |
2019 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Among the gastrointestinal hormones, the incretins: glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 have attracted interest because of their importance for the development and therapy of type 2 diabetes and obesity.
|
31815785 |
2020 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Antagonizing the glucose-dependent insulinotropic polypeptide (GIP) receptor may open up new therapeutic modalities in the treatment of diabetes and obesity.
|
28055305 |
2017 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
As such, blockade of GIP receptor (GIPR) action has been proposed as a means to counter insulin resistance, and improve metabolic status in obesity and related diabetes.
|
31733230 |
2020 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Augmentation of glucose mediated insulin release, the incretin effect, was discovered soon after GIP was first isolated and only much later was its important role in the pathogenesis of obesity, through mechanism other than insulin secretion, appreciated.
|
31539554 |
2019 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Given the established roles of glucose-dependent insulinotropic polypeptide (GIP) in promoting fat storage and bone formation, we assessed the contribution of GIP to obesity and osteopenia in ovariectomized mice with a gene encoding green fluorescent protein (GFP) inserted into the GIP locus, in which GIP was either reduced (GIP<sup>gfp/+</sup> ) or absent (GIP<sup>gfp/gfp</sup> ).
|
30451382 |
2019 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
GLP-1 and GIP combination is suggested as a promising therapeutic strategy for treatment of obesity and diabetes.
|
28610922 |
2017 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide-1 (GLP-1) is an incretin hormone used therapeutically in type 2 diabetes and obesity.
|
30726969 |
2019 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
In addition, observations in transgenic GIP receptor deficient mice indicate that GIP directly links overnutrition to obesity, therein playing a crucial role in the development of obesity and related metabolic disorders.
|
14607102 |
2003 |
Obesity
|
0.300 |
Biomarker
|
disease |
RGD |
In conclusion, both obese and diabetic rats had an impaired early-phase insulinotropic effect of GIP due to impaired gene expression of GIP-Rs which could be a potential target to prevent transition of obesity to diabetes and to improve insulin secretion in the latter.
|
18063845 |
2007 |
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In humans, genomewide association studies have identified single nucleotide polymorphisms (SNPs) in the GIPR gene that are strongly associated with body mass index (BMI); however, it is not clear whether genetic variations in the GIP gene are involved in the development of obesity.
|
25324507 |
2014 |
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this review, we first summarize our traditional understanding of the physiology of GIP and GLP-1, and our current knowledge of the relationships between GIP and GLP-1 and obesity and diabetes.
|
31392745 |
2020 |